Pfizer Inc. is doubling down on the booming weight-loss drug race , with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire obesity-drug developer Metsera.

"Pfizer, when it plays, plays big, and we will, as we did in COVID, as with Lipitor, as [with] Viagra, with all the medicines that we have invented and brought to the market, we will do the same with obesity," Bourla said Thursday on "Mornings with Maria."

The deal allows the pharmaceutical giant to secure the rights to new weight-loss treatments still in trials, entering a space already crowded with popular GLP-1 drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Pfizer expects to have its first weight-loss treatment on the market by the end of 2028, a mov

See Full Page